Strattera 10 mg kapsler, hårde 丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

strattera 10 mg kapsler, hårde

eli lilly danmark a/s - atomoxetinhydrochlorid - kapsler, hårde - 10 mg

Strattera 18 mg kapsler, hårde 丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

strattera 18 mg kapsler, hårde

eli lilly danmark a/s - atomoxetinhydrochlorid - kapsler, hårde - 18 mg

Strattera 25 mg kapsler, hårde 丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

strattera 25 mg kapsler, hårde

eli lilly danmark a/s - atomoxetinhydrochlorid - kapsler, hårde - 25 mg

Strattera 40 mg kapsler, hårde 丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

strattera 40 mg kapsler, hårde

eli lilly danmark a/s - atomoxetinhydrochlorid - kapsler, hårde - 40 mg

Strattera 60 mg kapsler, hårde 丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

strattera 60 mg kapsler, hårde

eli lilly danmark a/s - atomoxetinhydrochlorid - kapsler, hårde - 60 mg

Strattera 80 mg kapsler, hårde 丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

strattera 80 mg kapsler, hårde

eli lilly danmark a/s - atomoxetinhydrochlorid - kapsler, hårde - 80 mg

Verzenios 欧盟 - 丹麦文 - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - bryst neoplasmer - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Retsevmo 欧盟 - 丹麦文 - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Jaypirca 欧盟 - 丹麦文 - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - lymfom, mantelcelle - protein kinase hæmmere - treatment of mantle cell lymphoma (mcl).

Alimta 欧盟 - 丹麦文 - EMA (European Medicines Agency)

alimta

eli lilly nederland b.v. - pemetrexed - mesothelioma; carcinoma, non-small-cell lung - antineoplastiske midler - malignt pleura mesotheliomaalimta i kombination med cisplatin er indiceret til behandling af kemoterapi-naive patienter med inoperabel malignt pleura mesotheliom. non-small-cell lung canceralimta i kombination med cisplatin er angivet for den første linje behandling af patienter med lokalt fremskreden eller metastatisk ikke-small-cell lung cancer andre end overvejende planocellulært histologi. alimta er angivet som monoterapi til vedligeholdelse behandling af lokalt avanceret eller metastatisk ikke-small-cell lung cancer andre end overvejende planocellulært histologi hos patienter, hvis sygdom ikke har udviklet sig som følger umiddelbart efter platin-baseret kemoterapi. alimta er angivet som monoterapi for den anden linje behandling af patienter med lokalt fremskreden eller metastatisk ikke-small-cell lung cancer andre end overvejende planocellulært histologi.